Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition
Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Background
Kaposiform lymphangiomatosis (KLA) is a complex lymphatic anomaly involving most commonly the mediastinum, lung, skin and bones with few effective treatments. In recent years, RAS-MAPK pathway mutations were shown to underlie the pathogenesis of several complex lymphatic anomalies. Specifically, an activating NRAS mutation (p.Q61R) wa...
Alternative Titles
Full title
Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9440952
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9440952
Other Identifiers
ISSN
0031-3998
E-ISSN
1530-0447
DOI
10.1038/s41390-022-01986-0
